Efficacy & Safety of Ravidasvir + Sofosbuvir in Hepatitis C: STORM-C-1 Final Results

Soek-Siam Tan1, Sombat Thanprasertsuk2, Satawat Thongsawat3, Nicolas Salvadori4, Caroline Menétrey5, STORM-C-1 Research Team*
1Selayang Hospital, Department of Hepatology, Malaysia; 2Department of Disease Control, Ministry of Public Health, Bangkok, Thailand; 3Chiang Mai University, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand; 4Drugs for Neglected Diseases initiative, Geneva, Switzerland

Ravidasvir + sofosbuvir was well tolerated with excellent safety and efficacy in chronic HCV infection, including in difficult-to-treat populations (GT3, cirrhosis, prior HCV treatment, HIV co-infection).

BACKGROUND

Affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection in low and middle-income countries. STORM-C-1 study aimed to assess the efficacy and safety of ravidasvir plus sofosbuvir in adults chronically infected with HCV, with or without HIV co-infection.

METHODS

Trial design: Two-stage, open-label, phase 2/3 single-arm clinical trial conducted in 13 public hospitals in Malaysia and Thailand.

Participants: Chronic HCV infection, aged 18–69 years, without cirrhosis or with compensated cirrhosis (Child-Turcotte-Pugh class A), regardless of HCV genotype, HIV infection status or previous interferon-based HCV treatment.

Treatment: Once daily ravidasvir (200 mg) and sofosbuvir (400 mg) – 12 weeks for participants without cirrhosis or 24 weeks for those with cirrhosis.

Primary endpoint: Sustained virological response at 12 weeks after treatment (SVR12), defined as HCV RNA < LLOQ (<15 IU/mL in Malaysian and <12 IU/mL in Thai sites).

RESULTS

Baseline characteristics

Between September 2016 and September 2020, 603 participants were enrolled in STORM-C-1. Of these, 296 (49%) had genotype 3 infection, 162 (27%) had genotype 1a, 81 (13%) had genotype 1b, 61 (10%) had genotype 6 and 3 (<1%) had genotype 2. 238 (39%) had compensated cirrhosis, 192 (32%) had HIV co-infection, and 120 (20%) had received previous interferon-based treatment.

SVR by visit during post treatment period

Full analysis set (n=602)

Visit SVR 95% CI of SVR
Follow-up Wk 4 586/602 (97.3%) 96.7% to 98.5%
Follow-up Wk 12 583/602 (96.8%) 96.1% to 98.1%
Follow-up Wk 24 580/602 (96.3%) 94.5% to 97.7%

Overall SVR12 rate in per protocol set (n=580): 98.1% (95% CI: 96.6% to 99.0%). There were no significant drug-drug interactions with anti-retroviral therapies.

Adverse Events

Most common AEs: pyrexia (8%), URTI (6%), cough (6%), dizziness (5%), headache (5%).

One treatment emergent serious adverse event of acute kidney injury was assessed as possibly related to study treatment (sofosbuvir).

Treatment Emergent Adverse Events (TEAE) - Safety set (n=603)

<table>
<thead>
<tr>
<th>TEAE</th>
<th>RDV + SOF 12 weeks Non-Cirrhotic</th>
<th>RDV + SOF 24 weeks Cirrhotic</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 3 TEAE Any TEAE</td>
<td>16 (4%) [41]</td>
<td>17 (7%) [26]</td>
<td>33 (5%) [67]</td>
</tr>
<tr>
<td>Treatment related</td>
<td>2 (1%) [2]</td>
<td>3 (1%) [7]</td>
<td>5 (1%) [9]</td>
</tr>
<tr>
<td>Grade 4 TEAE Any TEAE</td>
<td>1 (&lt;1%) [1]</td>
<td>1 (&lt;1%) [1]</td>
<td>2 (&lt;1%) [2]</td>
</tr>
<tr>
<td>Treatment related</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
</tr>
<tr>
<td>Deaths Any TEAE</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
</tr>
<tr>
<td>Treatment related</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
<td>0 (0%) [0]</td>
</tr>
<tr>
<td>TE SAE</td>
<td>17 (5%) [20]</td>
<td>19 (8%) [22]</td>
<td>36 (6%) [42]</td>
</tr>
<tr>
<td>Treatment related</td>
<td>1 (&lt;1%) [1]</td>
<td>0 (0%) [0]</td>
<td>1 (&lt;1%) [1]</td>
</tr>
</tbody>
</table>

Note: Data are presented as number of subjects (percentage of subjects) [number of events]. Individual subjects may have experienced several adverse events of different grades.

Two additional deaths occurred after the 24-week post-treatment visit: both were unrelated to study treatment or to liver disease.

CONCLUSIONS

In this study, Ravidasvir with sofosbuvir was well tolerated with excellent safety and efficacy in HCV infection, including in difficult to treat populations, making it suitable for implementation in public health settings.

ACKNOWLEDGMENTS

Ministry of Health Malaysia, Ministry of Public Health Thailand, Pharco, Presidio, Clinical Research Center Malaysia, Dr Ahmad Yusof, Dr Louise Burrows, PHPT, DSMB members, the patients and their care givers.

Author contact: tanseoksiam@yahoo.com

*STORM-C-1 Research Team: Hajah Rosalita Hj Mohd Sali1, Muhammad Radzi Abu Hassan2, Haniza Omar3, Ancheeta Affingsarn4, Suparat Khemmarak5, Karawee Thetlik6, Hoi Poth Tae7, Alidja Che Aun8, Suresh Kumar9, Wah Kheong Chan9, Mahiran Mustafa10, Muhammad Firdaus Md Salleh11, Syuhada Dan Binti Adnan12, Isabelle Andreasson-Mayer13, Bernard Pecoul13, Laurent Brachet13, Vishal Goyal13, Isabela Ribeiro13, Francois Simon13, Sasikala Siva14, Alastair Swanson13, Tim R Cressey14, Nicole Ngo-Giang-Huong15, Sabine Yerly16, Shahnaz Murad17
1Hospital Ampang, Malaysia; 2Hospital Sultanah Bahiyah, Malaysia; Hospital Selayang, Malaysia; Thai Red Cross AIDS Research Centre; 3Barmerwerte Infectious Diseases Institute, Northrhine, Thailand; 4Nakornhospital, Chang Mai, Thailand; 5Hospital Tengku Ampuan Afzan Malaysia; 6Hospital Sungai Buloh, Malaysia; 7University of Malaya, Faculty of Medicine, Malaysia; 8Hospital Raju Perumpapan Zainab II, Kota Bharu, Malaysia; 9Hospital Sultanah Aminah, Department of Medicine, Johor Bahru, Malaysia; 10Hospital Sultanah Nur Zainah, Department of Hepatology/Gastroenterology, Kuala Terengganu, Malaysia; 11Drugs for Neglected Diseases initiative, Geneva, Switzerland; 12Chiang Mai University, Faculty of Associated Medical Sciences, PhP/TIDR, Chiang Mai, Thailand; 13Laboratory of Virology, Geneva University Hospitals, Switzerland; 14Ministry of Health, Kuala Lumpur, Malaysia.